Skip to main content
. 2023 Jan 26;7:12. doi: 10.1038/s41698-023-00350-7

Fig. 4. EGFR inhibitor sensitized ALK-rearranged lung cancer cells expressing high levels of EGFR to lorlatinib.

Fig. 4

a A925L, H2228, and JFCR-278 cells were incubated with lorlatinib (100 nmol/L), erlotinib (100 nmol/L), or a combination of lorlatinib and erlotinib for 72 h. Cell growth was determined using MTT assays. *P < 0.05 (one-way ANOVA). b Western blotting of A925L, H2228, and JFCR-278 cells treated with lorlatinib (100 nmol/L), erlotinib (100 nmol/L), or a combination of lorlatinib and erlotinib for 4 h. c A925L and H2228 cells were visualized using crystal violet staining following 9 days of treatment with lorlatinib (100 nmol/L), erlotinib (100 nmol/L), or combination of lorlatinib and erlotinib. d Western blotting of ALK-rearranged NSCLC parental cells. e Quantitative determination of the inhibition of cell viability of high- and low-EGFR-expressing ALK-rearranged NSCLC cells treated with lorlatinib in the presence or absence of erlotinib. Cell growth was determined using MTT assays. *P < 0.05 (paired Student’s t-test). Data are represented as mean ± S.D.